Dyne Therapeutics (NASDAQ:DYN) Sets New 1-Year Low – Here’s What Happened

Dyne Therapeutics, Inc. (NASDAQ:DYN)’s stock price reached a new 52-week low during trading on Wednesday . The company traded as low as $13.08 and last traded at $13.33, with a volume of 13398 shares trading hands. The stock had previously closed at $13.52.

Analysts Set New Price Targets

DYN has been the subject of a number of research analyst reports. Royal Bank of Canada reiterated an “outperform” rating and set a $45.00 price target on shares of Dyne Therapeutics in a report on Tuesday, January 14th. Chardan Capital reissued a “buy” rating and issued a $50.00 price target on shares of Dyne Therapeutics in a research note on Friday, January 10th. Guggenheim reaffirmed a “buy” rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. HC Wainwright reissued a “buy” rating and issued a $55.00 target price on shares of Dyne Therapeutics in a research report on Friday, January 10th. Finally, Robert W. Baird began coverage on Dyne Therapeutics in a research note on Friday, December 13th. They set an “outperform” rating and a $46.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $49.91.

Dyne Therapeutics Stock Performance

The company has a market cap of $1.36 billion, a price-to-earnings ratio of -3.75 and a beta of 1.11. The business has a 50-day simple moving average of $20.35 and a 200-day simple moving average of $30.15.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.25). Research analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Insider Buying and Selling

In related news, SVP Richard William Scalzo sold 1,455 shares of the stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total value of $40,914.60. Following the transaction, the senior vice president now directly owns 127,078 shares of the company’s stock, valued at $3,573,433.36. This trade represents a 1.13 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Oxana Beskrovnaya sold 2,334 shares of the business’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total transaction of $65,632.08. Following the completion of the sale, the insider now directly owns 201,685 shares of the company’s stock, valued at approximately $5,671,382.20. This trade represents a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 21,071 shares of company stock worth $606,476. Corporate insiders own 20.77% of the company’s stock.

Institutional Trading of Dyne Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in DYN. Quantbot Technologies LP purchased a new stake in shares of Dyne Therapeutics in the third quarter valued at about $34,000. Point72 DIFC Ltd purchased a new stake in Dyne Therapeutics during the 3rd quarter valued at approximately $36,000. US Bancorp DE raised its stake in Dyne Therapeutics by 776.9% during the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after acquiring an additional 1,212 shares during the last quarter. Values First Advisors Inc. acquired a new stake in Dyne Therapeutics during the 3rd quarter worth approximately $62,000. Finally, KBC Group NV grew its stake in shares of Dyne Therapeutics by 45.3% in the 4th quarter. KBC Group NV now owns 3,135 shares of the company’s stock valued at $74,000 after purchasing an additional 978 shares during the last quarter. 96.68% of the stock is owned by hedge funds and other institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.